Early test of experimental schizophrenia drug shows promise for safety
NCT ID NCT02181803
First seen May 03, 2026 · Last updated May 23, 2026 · Updated 4 times
Summary
This early-stage study tested an experimental drug called MK-8189 (elpipodect) in 55 people, including healthy volunteers and those with schizophrenia. The main goal was to check the drug's safety and how the body absorbs and processes it. Researchers also looked at brain activity changes. The study is complete, and results help decide if further testing is warranted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.